Myomo Inc’s recent filing unveils that its Officer Harry Kovelman acquired Company’s shares for reported $448.0 on Nov 04 ’24. In the deal valued at $3.70 per share,121 shares were bought.
Then, Harry Kovelman bought 121 shares, generating $467 in total proceeds.
Before that, Kovelman Harry sold 6,700 shares. Myomo Inc shares valued at $25,183 were divested by the Chief Medical Officer at a price of $3.76 per share. As a result of the transaction, Kovelman Harry now holds 123,556 shares, worth roughly $0.63 million.
Craig Hallum initiated its Myomo Inc [MYO] rating to a Buy in a research note published on July 31, 2024; the price target was $7. A number of analysts have revised their coverage, including Lake Street’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. H.C. Wainwright began covering MYO with “Buy” recommendation on December 15, 2023. ROTH Capital revised its rating on November 11, 2020. It rated MYO as “a Buy” which previously was an “a Neutral”.
Price Performance Review of MYO
On Tuesday, Myomo Inc [AMEX:MYO] saw its stock fall -5.56% to $5.10. Over the last five days, the stock has lost -15.84%. Myomo Inc shares have fallen nearly -20.81% since the year began. Nevertheless, the stocks have risen 72.88% over the past one year. While a 52-week high of $7.17 was reached on 01/07/25, a 52-week low of $2.51 was recorded on 02/25/25. SMA at 50 days reached $6.14, while 200 days put it at $4.61.
Levels Of Support And Resistance For MYO Stock
The 24-hour chart illustrates a support level at 4.95, which if violated will result in even more drops to 4.81. On the upside, there is a resistance level at 5.35. A further resistance level may holdings at 5.60. The Relative Strength Index (RSI) on the 14-day chart is 28.22, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.57, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.75%. Stochastics %K at 7.95% indicates the stock is a buying.
The most recent change occurred on May 27, 2020 when Dougherty & Company began covering the stock and recommended ‘”a Buy”‘ rating along with a $8.50 price target.
